Return bulk manufacturing production at the Limerick, Ireland facility to normal levels
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Apr 2026
- Due
- 30 Jun 2026
- Delivered
- 30 Jun 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“GAAP gross margin will continue to be negatively impacted until production returns to normal levels, which is expected by the end of the second quarter of 2026.”
What we found
Evidence strength A What the grades mean
Two July 2026 filings state that bulk manufacturing production at Limerick had returned to normal levels as of June 30, 2026, meeting the deadline.
-
A Regeneron Pharmaceuticals 8-K filed 2026-07-30
“As of the end of the second quarter of 2026, bulk manufacturing production returned to normal levels.” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-Q filed 2026-07-30
“As of June 30, 2026, bulk manufacturing production returned to normal levels.” ✓ confirmed on the page
Market reaction: the shares moved +5.3% against the S&P 500 over the three sessions around the disclosure (29 Jul 2026 to 3 Aug 2026). What this measures
Checked 11 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Facility other
- Indicative materiality
- Medium rules
- Action
- Return
- Deliverable
- Normal bulk manufacturing production at Limerick facility
- Where
- Limerick, Ireland
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-REGN-006359 · Corrections policy